C12Y 304/21008
Kallikrein
Official title: Kallikrein (3.4.21.8) (C12Y304/21034, C12Y304/21035 take precedence)
C12Y304/21008 (Kallikrein) appears on 5 US grants and 11 published applications in this corpus.
Search patents in C12Y- Granted patents
- 5
- Published applications
- 11
- Assignees
- 6
- Inventors
- 12
- Latest grant
- 28 Dec 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 1 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 2 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 1 | 2 |
| 2021 | 1 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 1 |
By publication year.
Recent patents
- Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis28 Dec 2021US 11,207,282 B2Indiana University Research and Technology Corporation
- Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis10 Mar 2020US 10,583,104 B2Indiana University Research and Technology Corporation
- Methods and materials for modulating resistance to apoptosis using KLK6 antisense and MIRNA molecules7 May 2019US 10,279,037 B2Mayo Foundation for Medical Education and Research
- Methods for increasing susceptibility to apoptosis by administering an inhibitor of kallikrein 6 polypeptide activity6 Jun 2017US 9,669,094 B2Mayo Foundation for Medical Education and Research
- Methods for modulating resistance to apoptosis using KLK610 Sep 2013US 8,530,427 B2Mayo Foundation for Medical Education and Research
- Treatment of skin diseases and disorders using inhibitors of kallikrein-related peptidases (klk)26 Oct 2023US 2023/0340488 A1Exicure Operating Company
- Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis14 Jul 2022US 2022/0218639 A1Indiana University Research and Technology Corporation
- Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins29 Oct 2020US 2020/0338123 A1CSL Behring GmbH
- Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis20 Aug 2020US 2020/0261386 A1Indiana University Research and Technology Corporation
- Methods and materials for modulating resistance to apoptosis19 Oct 2017US 2017/0296660 A1Mayo Foundation for Medical Education and Research
Most cited
By later US patents